TRIM21 and metastatic malignant neoplasm in the lymph nodes: We found that high TRIM21 expression predicted significant impact on clinical characteristics like decreased lymph node metastasis (RR = 1.12; 95% CI: 0.97–1.30; P < .001), tumor stage (RR = 1.06; 95% CI: 0.82–1.37; P < .001) and tumor grade (RR = 1.07; 95% CI: 0.56–2.05; P < .001).